Submitted:
17 November 2026
Posted:
19 November 2026
You are already at the latest version
Abstract
Inherited arrhythmia syndromes have traditionally been classified as either primary electrical disorders or structural cardiomyopathies, a framework that increasingly fails to capture the tissue-level abnormalities identified across this spectrum. Cardiac magnetic resonance (CMR) imaging has emerged as a pivotal tool in reframing this paradigm by combining precise ventricular phenotyping with myocardial tissue characterization. In classic channelopathies such as long QT syndrome and catecholaminergic polymorphic ventricular tachycardia, CMR remains primarily exclusionary, while in structural diseases such as arrhythmogenic and hypertrophic cardiomyopathy, it directly identifies the arrhythmogenic substrate through late gadolinium enhancement and parametric mapping. Brugada syndrome occupies an intermediate position, with emerging evidence of subtle right ventricular outflow tract abnormalities challenging its classification as a purely electrical disorder. This review examines the disease-specific diagnostic yield of CMR, its expanding role in risk stratification and implantable cardioverter-defibrillator decision-making, and future directions including artificial intelligence-driven analysis and genotype-phenotype correlation.
Keywords:
cardiac magnetic resonance
; inherited arrhythmia syndromes
; arrhythmogenic cardiomyopathy
; Brugada syndrome
; late gadolinium enhancement
; sudden cardiac death
; implantable cardioverter-defibrillator
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.